Dernières nouvelles pour Yerbae Brands (OTC:YERBF) Stock

Yerbae Brands Corp is a plant-based energy beverage company. It includes zero sugar, calories, or carbs and is powered by a natural caffeine source that uplifts without jitters, shakiness or a post-drink crash. The company delivers an enhanced experience that stimulates the body and focuses the mind without the jitters and crashes typically associated with energy drinks.

YERBAE BRANDS CORP by YERBAE BRANDS CORP.

Yerbae Brands Corp

Needham analyst Laura Martin reiterates Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Buy and maintains $84 price target.

News

Price Target

Reiteration

Analyst Ratings

Needham Reiterates Buy on Trade Desk, Maintains $84 Price Target

LULU: -23% &#x7C; <a href="https://www.benzinga.com//node/45803006">Lululemon Athletica shares are trading lower after the company cut its FY25 GAAP EPS guidance below estimates.</a>
&nbsp;
AVGO: -5% &#x7C; <a href="https://www.benzinga.com//node/45802886">Broadcom shares are trading lower following Q2 reported financial results.</a>
&nbsp;
TSLA: 6% &#x7C; <a href="https://www.benzinga.com//node/45807968">Trump Signals Truce With Elon Musk After Online Feud: 'It's Going Very Well, Never Done Better'</a>

Movers

Trading Ideas

AVGO

LULU

TSLA

Market-Moving News for June 6th

D. Boral Capital analyst Jason Kolbert maintains Artelo Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARTL#NASDAQ">ARTL</a>) with a Buy and maintains $6 price target.

ARTL

D. Boral Capital Maintains Buy on Artelo Biosciences, Maintains $6 Price Target

Needham analyst Ryan Koontz reiterates Ciena (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CIEN#NYSE">CIEN</a>) with a Buy and maintains $90 price target.

CIEN

Needham Reiterates Buy on Ciena, Maintains $90 Price Target

Phosphate and Potash Operations Outlook
Phosphate sales volumes for the second quarter of 2025 are expected to be 1.5-1.6 million tonnes, revised down from 1.7-1.9 million tonnes. 2025 full year production volume is now expected to be 7.0-7.3 million tonnes, revised down from 7.2-7.6 million tonnes.

Guidance

UPDATE: Mosaic Company Revises Outlook: Sees Q2 Phosphate Sales Volume At 1.5–1.6M Tonnes, Down From 1.7M–1.9M Prior; FY25 Output Trimmed To 7.0M–7.3M Tonnes Vs 7.2M-7.6M Tonnes Prior

RYVYL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) ("RYVYL" or the "Company"), a leading innovator of payment transaction solutions leveraging electronic payment technology, announced the securityholder of its remaining 8% Senior Convertible Note ("Note"), has converted the entire outstanding principal balance of $4.0 million and accrued interest of $136,000 into 7.1 million shares of common stock.

RVYL

RYVYL's Securityholder Converts Final $4M Senior Note, Including $136K Interest, Into 7.1M Shares

Earnings

MANU

Manchester United Q3 2025 Adj. EPS $(0.04) May Not Be Comparable To $(0.33) Estimate, Sales $207.26M Beat $202.47M Estimate

The most oversold stocks in the consumer staples sector presents an opportunity to buy into undervalued companies.
The RSI is a momentum indicator, which compares a stock&#8217;s strength on days when prices go up to its strength on days when prices go down. When compared to a stock&#8217;s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the <a href="https://www.benzinga.com/topic/rsi">RSI is below 30</a>, according to <a href="https://pro.benzinga.com/">Benzinga Pro</a>.
Here's the latest list of major oversold players in this sector, having an RSI near or below 30.
<h3 class="wp-block-heading">Constellation Brands Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STZ#NYSE">STZ</a>)</h3>
<ul class="wp-block-list">
<li>On June 2, Constellation Brands announced delivery of notices of redemption for 4.75% senior notes due 2025 and 5.00% senior notes due 2026. The company's stock fell around 9% over the past month and has a 52-week low of $160.46.</li>
<li>RSI Value: 26.8</li>
<li>STZ Price Action: Shares of Constellation fell 3.6% to close at $170.60 on Thursday.</li>
<li>Edge Stock Ratings: 18.63 Momentum score with Value at 14.10. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/quote/STZ"><img loading="lazy" decoding="async" width="441" height="183" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071110/image-87.png" alt="" class="wp-image-941078" style="width:325px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071110/image-87.png 441w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071110/image-87-300x124.png 300w" sizes="(max-width: 441px) 100vw, 441px" /></a></figure>
<h3 class="wp-block-heading">Coca-Cola Consolidated Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COKE#NASDAQ">COKE</a>)</h3>
<ul class="wp-block-list">
<li>On May 15, Coca-Cola Consolidated announced a $90 million investment in Columbus facility. &#8220;The investment we&#8217;ve made here in Columbus is evidence of our focus on growth in Columbus,&#8221; said Sam Meiner, VP, Mid-West Market Unit at Coca-Cola Consolidated. &#8220;This commitment to our teammates and production capabilities is a long-term dedication to improving how we serve the world&#8217;s best brands and flavors to our communities and the people of Ohio.&#8221; The company's stock fell around 10% over the past month and <a href="https://www.benzinga.com/quote/COKE">has a 52-week low</a> of $96.60.</li>
<li>RSI Value: 25.8</li>
<li>COKE Price Action: Shares of Coca-Cola Consolidated fell 1.4% to close at $106.17 on Thursday.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the trend in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606">COKE stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606"><img loading="lazy" decoding="async" width="927" height="851" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88.png" alt="" class="wp-image-941079" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88.png 927w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071215/image-88-768x705.png 768w" sizes="(max-width: 927px) 100vw, 927px" /></a></figure>
<h3 class="wp-block-heading">Diageo PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DEO#NYSE">DEO</a>)</h3>
<ul class="wp-block-list">
<li>On May 19, Diageo reported a third-quarter fiscal 2025 trading update that showed steady growth in organic net sales and progress on its operational transformation efforts. The maker of Smirnoff and Guinness posted $4.4 billion in net sales for the quarter ended March 31, marking a 2.9% increase year-over-year. Organic net sales rose 5.9%, driven by stronger pricing and shipment volumes. The company's stock fell around 8% over the past month and has a 52-week <a href="https://www.benzinga.com/quote/DEO">low of $100.72.</a></li>
<li>RSI Value: 29</li>
<li>DEO Ltd Price Action: Shares of Diageo fell 5.1% to close at $105.20 on Thursday.</li>
<li>Benzinga Pro&#8217;s signals feature notified of a potential breakout in <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606">DEO shares</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0606"><img loading="lazy" decoding="async" width="862" height="832" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89.png" alt="" class="wp-image-941080" style="width:661px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89.png 862w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89-300x290.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/06071542/image-89-768x741.png 768w" sizes="(max-width: 862px) 100vw, 862px" /></a></figure>
Learn more about BZ Edge Rankings—click to see scores for other stocks in the sector and s<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound">ee how they compare.</a>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45789751/jim-cramer-likes-dominion-energy-but-isnt-a-fan-of-this-real-estate-stock">Jim Cramer Likes Dominion Energy, But Isn&#8217;t &#8216;A Fan&#8217; Of This Real Estate Stock</a> </li>
</ul>
Photo via Shutterstock

Long Ideas

Pre-Market Outlook

Markets

COKE

Top 3 Risk Off Stocks That Could Blast Off This Month

Needham analyst Mike Cikos reiterates Cellebrite DI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLBT#NASDAQ">CLBT</a>) with a Buy and maintains $24 price target.

CLBT

Needham Reiterates Buy on Cellebrite DI, Maintains $24 Price Target

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") announces that the proposed private placement offering announced June 5, 2025 has been increased from C$2,500,000 to C$3,080,000. Fury now intends to privately place with a small group of accredited and institutional investors in Canada a total of 4,000,000 flow-through common shares (the "Shares") of the Company, at a price of C$0.77 per Share for total gross proceeds of C$3,080,000 (the "Offering"). This offering figure could increase by up to approximately 15.4% if a strategic investor elects to exercise its pre-emptive participation rights disclosed in a <a href="https://www.globenewswire.com/Tracker?data=HQaYc8Cgq_iu2dRsUPGUu4P8s3eHB2eh9WbW-ZLoEWjXoCqjvRLyTfYk3hp6kqzAmBb84_tbBVoR_n5MFK0Ixq9Z6MdXWXYjmhnHy6AtbvrgY_wLYJ1ItwqiqvhkOwikomCI1oUBmQMZQ53iXZrkOtyfCPzsDPY_b__Zik8XVFI=">May 27, 2025 news release</a>.
The Offering is expected to close on or about June 19, 2025 (the "Closing Date"), subject to execution of subscription agreements and customary closing conditions, including receipt of all necessary approvals, including the approval of the Toronto Stock Exchange ("TSX") and the NYSE American LLC. Other previously announced terms and conditions remain the same.

FURY

Fury Gold Mines Increases Proposed Private Placement Offering From C$2.50M To C$3.08M

G-III Apparel Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GIII#NASDAQ">GIII</a>) is looking for Q2 Adj EPS of $0.02-$0.12 vs $0.48 analyst estimate. Q2 Revenue expected to be more than $570.00M vs $621.00M Est

GIII

G-III Apparel Group Sees Q2 EPS $0.02-$0.12; Q2  Revenue Expected To Be Approximately $570.00M vs $621.00M Est

PRPH

ProPhase Labs Forms Clinical Science Advisory Board To Support Clinical Adoption And Commercialization Of Breakthrough BE-Smart Molecular Test For Esophageal Disease

D. Boral Capital analyst Jason Kolbert maintains AVITA Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCEL#NASDAQ">RCEL</a>) with a Buy and maintains $19 price target.

RCEL

D. Boral Capital Maintains Buy on AVITA Medical, Maintains $19 Price Target

Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) (the "Company" or "Sandisk") announced today the pricing of a secondary public offering (the "Offering") of 18,534,581 shares of its common stock (the "SNDK Shares") currently owned by Western Digital Corporation, the Company's former parent ("WDC"). The size of the offering reflects an increase from the 17,000,000 shares of common stock originally proposed to be sold. The SNDK Shares will be offered at a public offering price of $38.50 per share. Sandisk is not selling any shares of common stock and will not receive any proceeds from the sale of the SNDK Shares in the Offering or from the debt-for-equity exchange.

SNDK

Sandisk Announces Pricing For Expanded Secondary Offering; WDC to Sell 18.5M Shares, Priced at $38.50/Shr

Needham analyst Tom Nikic maintains Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) with a Buy and lowers the price target from $366 to $317.

Needham Maintains Buy on Lululemon Athletica, Lowers Price Target to $317

Manchester United (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MANU#NYSE">MANU</a>) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.33) by 87.88 percent. This is a 87.1 percent increase over losses of $(0.31) per share from the same period last year. The company reported quarterly sales of $202.03 million which missed the analyst consensus estimate of $202.47 million by 0.22 percent. This is a 16.53 percent increase over sales of $173.37 million the same period last year.

Earnings Beats

Earnings Misses

Manchester United Q3 Adj. EPS $(0.04) Beats $(0.33) Estimate, Sales $202.03M Miss $202.47M Estimate

G-III Apparel Anticipates Unmitigated Cost Of Tariffs On Goods Imported Into The United States Will Result In Additional Expense Of $135M, Which Will Primarily Be Weighted To The Second Half Of The Year

<a href="https://www.globenewswire.com/Tracker?data=n4VAc1wDtm5Gx7yfSA9G9Bdm2S_5VbQKkJDwPg3B940asDE5ZukU5_AOibtKC3kemI6XkVzqXtwCjRwSJvfq1cpQeANnCCU7jEhQPnli8rQ=">BioCryst Pharmaceuticals, Inc. </a>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCRX#NASDAQ">BCRX</a>) today announced that, following a positive recommendation from the Zorginstituut Nederland, ORLADEYO&#xAE; (berotralstat) has been approved for the routine prevention of hereditary angioedema (HAE) attacks in patients aged 12 years and older. This reimbursement approval in the Netherlands marks national reimbursement for ORLADEYO across all major European countries, providing HAE patients with access to the first oral, once-daily preventive therapy.

BCRX

Netherlands Approves BioCryst Pharma's ORLADEYO For Hereditary Angioedema Prevention, Expanding National Access Across Europe

G-III Apparel Has Withdrawn Its Net Income, Non-GAAP Net Income And Adjusted EBITDA Guidance For FY26 Due To Uncertainty Around Tariffs And Related Macroeconomic Conditions

Strategy&#x2122; (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSTR#NASDAQ">MSTR</a>) today announced the pricing of its initial public offering on June 5, 2025 of 11,764,700 shares of 10.00% Series A Perpetual Stride Preferred Stock (the "STRD Stock"), at a public offering price of $85.00 per share. The issuance and sale of the STRD Stock are scheduled to settle on June 10, 2025, subject to customary closing conditions.
Strategy estimates that the net proceeds to it from the offering will be approximately $979.7 million, after deducting the underwriting discounts and commissions and Strategy's estimated offering expenses. Strategy intends to use the net proceeds from the offering for general corporate purposes, including the acquisition of bitcoin and for working capital.

IPOs

MSTR

Strategy Prices IPO Of 11.8M Shares Of 10.00% Series A Perpetual Stride Preferred Stock At Public Offering Price Of $85.00/Shr

Press Releases

Yerbaé Expands Distribution with Four New Partnerships, Creating Synergies with Safety Shot's Operations

Yerbae Expands Midwest Convenience Store Presence with Casey's General Stores Authorization

YERBAÉ BRANDS CORP. ANNOUNCES LOAN AGREEMENT WITH MAXIMCASH

Safety Shot, Inc. Terminates At-the-Market Equity Offering, Reaffirms Strong Financial Position and Growth Trajectory

Yerbae Expands Colorado Distribution Through Eagle Rock Distributing and King Soopers, Seeking to Mirror Safety Shot's Success in Major Supermarket Chains

Yerbaé Expands Georgia Distribution Through Savannah Distributing Company Inc. and Announces Grant of Equity Incentives

Safety Shot CEO Jarrett Boon and Yerbaé CEO Todd Gibson Join FORCE Family Webinar to Discuss How Safety Shot Plans to Disrupt the Functional Wellness and Beverage Market

Comments

Yerbae Brands

Actualités

Dernières nouvelles pour Yerbae Brands (OTC:YERBF) Stock

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL